Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

NCT02582684 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

122

Enrollment

NETWORK

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: Dolutegravir
DRUG: Lamivudine

Sponsor

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Collaborators

[object Object]